JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (7): 45-49.doi: 10.6040/j.issn.1671-7554.0.2013.750

Previous Articles     Next Articles

A randomized clinical trial of ten-day concomitant, sequential and bismuth-based quadruple therapies for Helicobacter pylori

LI Yueyue, ZUO Xiuli, JI Rui, CHEN Feixue, ZHAO Hongyu, WANG Han, GUO Jing, ZHANG Jingyuan, FU Shanshan, LIU Jianwei, LI Yanqing   

  1. Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2013-12-13 Revised:2014-06-12 Online:2014-07-10 Published:2014-07-10

Abstract: Objective To determine the best empiric regimens to eradicate Helicobacter pylori (Hp) in daily clinical work by comparing the efficacy of ten-day concomitant, sequential and bismuth-based quadruple therapies. Methods A total of 226 patients with H.pylori infection proved by rapid urease test (RUT) were randomly divided into 3 groups, and received concomitant therapy (omeprazole 20 mg, amoxicillin 1 000 mg, clarithromycin 500 mg and tinidazole 500 mg), sequential therapy (omeprazole 20 mg, amoxicillin 1 000 mg for the first 5 days, followed by omeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg for another 5 days), and bismuth-based therapy (omeprazole 20 mg, amoxicillin 1 000 mg, clarithromycin 500 mg and colloidal bismuth pectin 200 mg), respectively. All regimens were taken twice a day for 10 days. Hp status was confirmed by 13C-urea breath test 6 weeks after completion of treatment, and negative result was considered as successful in Hp eradication. Results In intention-to-treat analysis, the eradication rates of concomitant therapy, sequential therapy and bismuth-based therapy were 85.6%, 70.7%, and 85.3%, respectively. Either concomitant therapy or bismuth-based therapy was significantly superior to sequential therapy (P<0.05). In per-protocol analysis, the eradication rates of the 3 regimens were 87.8%, 82.8% and 88.9%, respectively.And there was no statistic significance between any two of the three groups (P>0.05). Conclusion Ten-day bismuth-based therapy can be adopted as the best empiric regimen to cure Hp infection in clinical work.

Key words: Helicobacter pylori, Concomitant therapy, Sequential therapy, Bismuth-based therapy

CLC Number: 

  • R573
[1] McColl K E. Clinical practice. Helicobacter pylori infection[J]. N Engl J Med, 2010, 362(17):1597-1604.
[2] Suerbaum S, Michetti P. Helicobacter pylori infection[J]. N Engl J Med, 2002, 347(15):1175-1186.
[3] Hopkins R J, Girardi L S, Turney E A. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review[J]. Gastroenterology, 1996, 110(4):1244-1252.
[4] Graham D Y, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance[J]. Gut, 2010, 59(8):1143-1153.
[5] Malfertheiner P, Megraud F, O'Morain C A, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report[J]. Gut, 2012, 61(5):646-664.
[6] Georgopoulos S D, Xirouchakis E, Martinez-Gonzalez B, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of helicobacter pylori in a high clarithromycin resistance area[J]. Helicobacter, 2013, 18(6):459-467.
[7] Huang Y K, Wu M C, Wang S S, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication[J]. J Dig Dis, 2012, 13(4):232-238.
[8] Lim J H, Lee D H, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study[J]. Helicobacter, 2013, 18(3):180-186.
[9] Yang Y J, Sheu B S. Sequential therapy in childhood Helicobacter pylori eradication: emphasis on drug compliance[J]. J Pediatr, 2011, 159(4):700.
[10] Lee M, Kemp J A, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy[J]. Arch Intern Med, 1999, 159(19):2312-2316.
[11] Manfredi M, Bizzarri B, Sacchero R I, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy[J]. Helicobacter, 2012, 17(4):254-263.
[12] Kadayifci A, Uygun A, Polat Z, et al. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori[J]. Turk J Gastroenterol, 2012, 23(1):8-13.
[13] 刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].胃肠病学, 2012, 51(10):618-625.
[14] Malfenheiner P, Bazzoli F, Delchier J C, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, open-1abel, non-inferiority, phase 3 trial[J]. Lancet, 2011, 377(9769):905-913.
[15] Zheng Q, Chen W J, Lu H, et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance[J]. J Dig Dis, 2010,11(5):313-318.
[16] Ford A C, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis[J]. World J Gastroenterol, 2008,14(48):7361-7370.
[17] Graham D Y, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12(4):275-278.
[18] Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy[J]. BMJ, 2013, 347: f4587. doi: 10.1136/bmj.f4587.
[19] Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China[J]. Helicobacter, 2013, 18(4):274-279.
[20] Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China[J]. Helicobacter, 2010, 15(5):460-466.
[21] Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication[J]. Aliment Pharmacol Ther, 2000, 14(12):1639-1643.
[22] Romano M, Iovene M R, Montella F, et al. Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection[J]. Am J Gastroenterol, 2000, 95(11):3317-3318.
[23] Hsu P I, Chen W C, Tsay F W, et al. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for helicobacter pylori infection after failure of sequential therapy[J]. Helicobacter, 2014, 19(1):74-79.
[24] Rodríguez-Torres M, Salgado-Mercado R, Ríos-Bedoya C F, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin[J]. Dig Dis Sci, 2005, 50(4):634-639.
[1] XU Cui, WANG Tao, ZHOU Ping. Immunohistochemical analysis of Helicobacter pylori infection in children [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 81-84.
[2] WANG Hui. Clinical observation of triple therapy of moxifloxacin and esomeprazole magnesium for Helicobacter Pylori [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 52-56.
[3] YANG Xue, QIU Chunhua, LEI Lei, HU Xiao. Characteristics of gastric polyps and correlation with helicobacter pylori infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 41-44.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!